IDH1 and glioblastoma: Given the heterogeneity of clinical glioblastoma specimens, we further correlated these data with tumour cell morphological subtypes, specific patterns of vascular proliferation and known genetic prognostic markers such as IDH1 mutation [27] and MGMT promoter methylation [28].